These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25483082)

  • 41. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
    Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL?
    Rumpold H; Webersinke G
    Curr Cancer Drug Targets; 2011 Jan; 11(1):3-19. PubMed ID: 21062244
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 44. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
    Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
    Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.
    Cramer-Morales K; Nieborowska-Skorska M; Scheibner K; Padget M; Irvine DA; Sliwinski T; Haas K; Lee J; Geng H; Roy D; Slupianek A; Rassool FV; Wasik MA; Childers W; Copland M; Müschen M; Civin CI; Skorski T
    Blood; 2013 Aug; 122(7):1293-304. PubMed ID: 23836560
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.
    Loncarevic IF; Römer J; Starke H; Heller A; Bleck C; Ziegler M; Fiedler W; Liehr T; Clement JH; Claussen U
    Genes Chromosomes Cancer; 2002 Jun; 34(2):193-200. PubMed ID: 11979553
    [TBL] [Abstract][Full Text] [Related]  

  • 47.
    Pagani IS; Dang P; Kommers IO; Goyne JM; Nicola M; Saunders VA; Braley J; White DL; Yeung DT; Branford S; Hughes TP; Ross DM
    Haematologica; 2018 Dec; 103(12):2026-2032. PubMed ID: 29976745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis.
    Sekine Y; Ikeda O; Mizushima A; Ueno Y; Muromoto R; Yoshimura A; Kanakura Y; Oritani K; Matsuda T
    Oncogene; 2012 Oct; 31(40):4384-96. PubMed ID: 22231445
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells.
    Mancini M; Leo E; Takemaru K; Campi V; Borsi E; Castagnetti F; Gugliotta G; Santucci MA; Martinelli G
    Cell Signal; 2013 Sep; 25(9):1820-7. PubMed ID: 23707389
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR; Yang F; Press RD
    Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia.
    Panuzzo C; Crivellaro S; Carrà G; Guerrasio A; Saglio G; Morotti A
    PLoS One; 2014; 9(10):e110682. PubMed ID: 25343485
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia.
    Singh MM; Irwin ME; Gao Y; Ban K; Shi P; Arlinghaus RB; Amin HM; Chandra J
    Cancer; 2012 Jul; 118(13):3433-45. PubMed ID: 22139798
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bcr/Abl interferes with the Fanconi anemia/BRCA pathway: implications in the chromosomal instability of chronic myeloid leukemia cells.
    Valeri A; Alonso-Ferrero ME; Río P; Pujol MR; Casado JA; Pérez L; Jacome A; Agirre X; Calasanz MJ; Hanenberg H; Surrallés J; Prosper F; Albella B; Bueren JA
    PLoS One; 2010 Dec; 5(12):e15525. PubMed ID: 21203397
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Different modes of interaction by TIAR and HuR with target RNA and DNA.
    Kim HS; Wilce MC; Yoga YM; Pendini NR; Gunzburg MJ; Cowieson NP; Wilson GM; Williams BR; Gorospe M; Wilce JA
    Nucleic Acids Res; 2011 Feb; 39(3):1117-30. PubMed ID: 21233170
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Control of the ATP synthase beta subunit expression by RNA-binding proteins TIA-1, TIAR, and HuR.
    Izquierdo JM
    Biochem Biophys Res Commun; 2006 Sep; 348(2):703-11. PubMed ID: 16890199
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Monoubiquitinated Fanconi anemia D2 (FANCD2-Ub) is required for BCR-ABL1 kinase-induced leukemogenesis.
    Koptyra M; Stoklosa T; Hoser G; Glodkowska-Mrowka E; Seferynska I; Klejman A; Blasiak J; Skorski T
    Leukemia; 2011 Aug; 25(8):1259-67. PubMed ID: 21519342
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression.
    Bueno MJ; Pérez de Castro I; Gómez de Cedrón M; Santos J; Calin GA; Cigudosa JC; Croce CM; Fernández-Piqueras J; Malumbres M
    Cancer Cell; 2008 Jun; 13(6):496-506. PubMed ID: 18538733
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Insulin-like growth factor-I receptor is suppressed through transcriptional repression and mRNA destabilization by a novel energy restriction-mimetic agent.
    Chu PC; Kulp SK; Chen CS
    Carcinogenesis; 2013 Dec; 34(12):2694-705. PubMed ID: 23864387
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.
    Agarwal A; Mackenzie RJ; Besson A; Jeng S; Carey A; LaTocha DH; Fleischman AG; Duquesnes N; Eide CA; Vasudevan KB; Loriaux MM; Firpo E; Cortes JE; McWeeney S; O'Hare T; Roberts JM; Druker BJ; Deininger MW
    Blood; 2014 Nov; 124(22):3260-73. PubMed ID: 25293778
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TIF1β activates leukemic transcriptional program in HSCs and promotes BCR::ABL1-induced myeloid leukemia.
    Morii M; Kubota S; Iimori M; Yokomizo-Nakano T; Hamashima A; Bai J; Nishimura A; Tasaki M; Ando Y; Araki K; Sashida G
    Leukemia; 2024 Jun; 38(6):1275-1286. PubMed ID: 38734786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.